My watch list
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Dalbavancin, a novel second-generation lipoglycopeptide agent, belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with MRSA.
Additional recommended knowledge
It possesses in vitro activity against a variety of gram-positive pathogens including MRSA and MRSE. It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.
References and notes
- ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
- ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMID 17362476.
- ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524.
- ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
- ^ UPDATE 1-Pfizer says US FDA wants more data on antibiotic
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dalbavancin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE